Prevention of Malaria

MALARONE® is indicated for the prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported.

Treatment of Malaria

MALARONE is indicated for the treatment of acute, uncomplicated P. falciparum malaria. MALARONE has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance.

The daily dose should be taken at the same time each day with food or a milky drink. In the event of vomiting within 1 hour after dosing, a repeat dose should be taken.

MALARONE may be crushed and mixed with condensed milk just prior to administration to patients who may have difficulty swallowing tablets.

Prevention of Malaria

Start prophylactic treatment with MALARONE 1 or 2 days before entering a malaria-endemic area and continue daily during the stay and for 7 days after return.

Adults: One MALARONE Tablet (adult strength = 250 mg atovaquone/100 mg proguanil hydrochloride) per day.

Pediatric Patients: The dosage for prevention of malaria in pediatric patients is based upon body weight (Table 1).

Table 1: Dosage for Prevention of Malaria in Pediatric Patients

Treatment of Acute Malaria

Adults: Four MALARONE Tablets (adult strength; total daily dose 1 g atovaquone/400 mg proguanil hydrochloride) as a single daily dose for 3 consecutive days.

Pediatric Patients: The dosage for treatment of acute malaria in pediatric patients is based upon body weight (Table 2).

Table 2: Dosage for Treatment of Acute Malaria in Pediatric Patients

Renal Impairment

Do not use MALARONE for malaria prophylaxis in patients with severe renal impairment (creatinine clearance < 30 mL/min) [See CONTRAINDICATIONS]. Use with caution for the treatment of malaria in patients with severe renal impairment, only if the benefits of the 3 day treatment regimen outweigh the potential risks associated with increased drug exposure. No dosage adjustments are needed in patients with mild (creatinine clearance 50 to 80 mL/min) or moderate (creatinine clearance 30 to 50 mL/min) renal impairment. [See CLINICAL PHARMACOLOGY.]

Dosage Forms And Strengths

Each MALARONE Tablet (adult strength) contains 250 mg atovaquone and 100 mg proguanil hydrochloride. MALARONE Tablets are pink, film-coated, round, biconvex tablets engraved with “GX CM3” on one side.

Each MALARONE Pediatric Tablet contains 62.5 mg atovaquone and 25 mg proguanil hydrochloride. MALARONE Pediatric Tablets are pink, film-coated, round, biconvex tablets engraved with “GX CG7” on one side.

Storage And Handling

MALARONE Tablets, containing 250 mg atovaquone and 100 mg proguanil hydrochloride.

Bottle of 100 tablets with child-resistant closure (NDC 0173-0675-01).
Unit Dose Pack of 24 (NDC 0173-0675-02).

MALARONE Pediatric Tablets, containing 62.5 mg atovaquone and 25 mg proguanil hydrochloride.

Bottle of 100 tablets with child-resistant closure (NDC 0173-0676-01).

Storage Conditions

Store at 25°C (77°F). Temperature excursions are permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature).

GlaxoSmithKline Research Triangle Park, NC 27709. Revised: February 2013

Last reviewed on RxList: 3/19/2013
This monograph has been modified to include the generic and brand name in many instances.